Purdue's Support For OTC Naloxone Would Continue In Bankruptcy

Bankrupt Purdue proposes continued funding for developing OTC naloxone product through firm to sell ‘millions of doses’ of the emergency opioid overdose product at low or no cost. Harm Reduction Therapeutics, which previously received funding from Purdue, has pushed back target date for NDA until early 2021 for its OTC naloxone nasal spray.

Dollar bills

Purdue Pharma LP’s proposed bankruptcy settlement would launch a company dedicated to developing an OTC naloxone and to sell “millions of doses” of the emergency opioid overdose product at low or no cost.

In its 16 September filing for Chapter 11 bankruptcy protection, the firm proposes spending $10bn on developing nalmefene addiction...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America